Canaccord Adams initiates coverage on Myriad Genetics (Nasdaq: MYGN) with a Sell rating and a $41.50 price target.

The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE